193 related articles for article (PubMed ID: 14552066)
1. Iron and Parkinson's disease: chelators to the rescue?
Levenson CW
Nutr Rev; 2003 Sep; 61(9):311-3. PubMed ID: 14552066
[TBL] [Abstract][Full Text] [Related]
2. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders.
Gassen M; Youdim MB
Pharmacol Toxicol; 1997 Apr; 80(4):159-66. PubMed ID: 9140134
[TBL] [Abstract][Full Text] [Related]
3. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer's and Parkinson's diseases.
Singh YP; Pandey A; Vishwakarma S; Modi G
Mol Divers; 2019 May; 23(2):509-526. PubMed ID: 30293116
[TBL] [Abstract][Full Text] [Related]
4. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
5. Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease.
Ben-Shachar D; Eshel G; Riederer P; Youdim MB
Ann Neurol; 1992; 32 Suppl():S105-10. PubMed ID: 1510367
[TBL] [Abstract][Full Text] [Related]
6. Iron chelation and neuroprotection in neurodegenerative diseases.
Li X; Jankovic J; Le W
J Neural Transm (Vienna); 2011 Mar; 118(3):473-7. PubMed ID: 21161300
[TBL] [Abstract][Full Text] [Related]
7. Iron and Parkinson's disease.
Di Lorenzo F
Neuro Endocrinol Lett; 2015; 36(1):24-7. PubMed ID: 25789591
[TBL] [Abstract][Full Text] [Related]
8. Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?
Kaur D; Andersen JK
Aging Cell; 2002 Oct; 1(1):17-21. PubMed ID: 12882349
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging.
Bar-Am O; Amit T; Kupershmidt L; Aluf Y; Mechlovich D; Kabha H; Danovitch L; Zurawski VR; Youdim MB; Weinreb O
Neurobiol Aging; 2015 Mar; 36(3):1529-42. PubMed ID: 25499799
[TBL] [Abstract][Full Text] [Related]
10. Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.
Devos D; Cabantchik ZI; Moreau C; Danel V; Mahoney-Sanchez L; Bouchaoui H; Gouel F; Rolland AS; Duce JA; Devedjian JC;
J Neural Transm (Vienna); 2020 Feb; 127(2):189-203. PubMed ID: 31912279
[TBL] [Abstract][Full Text] [Related]
11. Iron in neurodegenerative disorders: being in the wrong place at the wrong time?
Apostolakis S; Kypraiou AM
Rev Neurosci; 2017 Nov; 28(8):893-911. PubMed ID: 28792913
[TBL] [Abstract][Full Text] [Related]
12. Neurodegenerative diseases and therapeutic strategies using iron chelators.
Ward RJ; Dexter DT; Crichton RR
J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological manipulation of ataxia-telangiectasia kinase activity as a treatment for Parkinson's disease.
Edwin Shackelford R; Manuszak RP; Heard SC; Link CJ; Wang S
Med Hypotheses; 2005; 64(4):736-41. PubMed ID: 15694690
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
[TBL] [Abstract][Full Text] [Related]
15. Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson's disease.
Lewis FW; Fairooz S; Elson JL; Hubscher-Bruder V; Brandel J; Soundararajan M; Smith D; Dexter DT; Tétard D; Pienaar IS
Arch Toxicol; 2020 Mar; 94(3):813-831. PubMed ID: 32078022
[TBL] [Abstract][Full Text] [Related]
16. Dopamine D₂/D₃ agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson's disease.
Gogoi S; Antonio T; Rajagopalan S; Reith M; Andersen J; Dutta AK
ChemMedChem; 2011 Jun; 6(6):991-5. PubMed ID: 21567969
[No Abstract] [Full Text] [Related]
17. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.
Weinreb O; Mandel S; Youdim MBH; Amit T
Free Radic Biol Med; 2013 Sep; 62():52-64. PubMed ID: 23376471
[TBL] [Abstract][Full Text] [Related]
18. Targeting chelatable iron as a therapeutic modality in Parkinson's disease.
Devos D; Moreau C; Devedjian JC; Kluza J; Petrault M; Laloux C; Jonneaux A; Ryckewaert G; Garçon G; Rouaix N; Duhamel A; Jissendi P; Dujardin K; Auger F; Ravasi L; Hopes L; Grolez G; Firdaus W; Sablonnière B; Strubi-Vuillaume I; Zahr N; Destée A; Corvol JC; Pöltl D; Leist M; Rose C; Defebvre L; Marchetti P; Cabantchik ZI; Bordet R
Antioxid Redox Signal; 2014 Jul; 21(2):195-210. PubMed ID: 24251381
[TBL] [Abstract][Full Text] [Related]
19. Dopamine complexes of iron in the etiology and pathogenesis of Parkinson's disease.
Arreguin S; Nelson P; Padway S; Shirazi M; Pierpont C
J Inorg Biochem; 2009 Jan; 103(1):87-93. PubMed ID: 18976814
[TBL] [Abstract][Full Text] [Related]
20. Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration.
Masaldan S; Bush AI; Devos D; Rolland AS; Moreau C
Free Radic Biol Med; 2019 Mar; 133():221-233. PubMed ID: 30266679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]